Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UBX 306

Next Previous
Drug Profile

UBX 306

Alternative Names: UBX-306; UBX-306-1; UBX-306-2; UBX-306-3

Latest Information Update: 06 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ubix Therapeutics
  • Developer NeoImmuneTech
  • Class Antineoplastics
  • Mechanism of Action Haematopoietic progenitor kinase 1 degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 25 Apr 2025 Preclinical trials in Cancer in USA (PO)
  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-20225)
  • 21 Feb 2024 Early research in Cancer in USA (unspecified route) prior to February 2024 (Ubix Therapeutics pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top